# MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)

> **NCT06212466** · — · COMPLETED · sponsor: **Genetesis Inc.** · enrollment: 136 (actual)

## Conditions studied

- Ischemic Heart Disease
- Coronary Microvascular Disease
- Angina
- Myocardial Ischemia

## Interventions

- **DEVICE:** CardioFlux

## Key facts

- **NCT ID:** NCT06212466
- **Lead sponsor:** Genetesis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-03
- **Primary completion:** 2025-04-15
- **Final completion:** 2025-04-15
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06212466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06212466, "MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06212466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*